All Articles

To provide analysis of the intracranial activity of tepotinib in patients with METex14 skipping NSCLC with BM from the VISION study to aid oncology nurse navigators who manage this population of patients.

Category IX: Clinical Research

MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

AONN+ Conference Abstracts

November 2022 Vol 13, No 11

MF is a rare bone marrow cancer characterized by fibrosis, abnormal blood cell production, and dysregulated JAK/STAT signaling.^1,2

Category IX: Clinical Research

Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial

AONN+ Conference Abstracts

November 2022 Vol 13, No 11

To assess OS at an updated cutoff with additional follow-up.

Category IX: Clinical Research

Phase 2 Study of Cemiplimab in Patients with Locally Advanced Basal-Cell Carcinoma After Hedgehog Inhibitor Therapy: Long-Term Follow-Up

AONN+ Conference Abstracts

November 2022 Vol 13, No 11

Here, we present the long-term follow-up data at up to 40 months.

Category IX: Clinical Research

Primary Analysis of Phase 2 Results for Cemiplimab in Patients with mBCC Who Progressed on or Were Intolerant to Hedgehog Inhibitors

AONN+ Conference Abstracts

November 2022 Vol 13, No 11

Here, we present the primary analysis of the mBCC cohort.

Category IX: Clinical Research

Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) (MOMENTUM)

AONN+ Conference Abstracts

November 2022 Vol 13, No 11

MMB, an oral JAK1/2 and ACVR1/ALK2 inhibitor, was evaluated (vs DAN) in a pivotal phase 3 study of MF patients previously treated with a JAK inhibitor (JAKi). This subgroup analysis evaluated MOMENTUM patients with baseline platelet counts ≤150 × 10⁹/L.

Category IX: Clinical Research

Upper Gastrointestinal (GI) Morbidity and Gastric Acid–Reducing Agent (GARA) Use Among Oncolytic-Treated Patients with Non-Hodgkin Lymphomas: Nursing Perspective Insights

Clinical Research, AONN+ Conference Abstracts

November 2022 Vol 13, No 11

To evaluate the epidemiology of upper GI morbidity, peptic ulcer risk, and prescription GARA use among patients with MCL or CLL/SLL and provide the nursing perspective on GARA use in oncology patient care.

Navigating Oral Therapy in Breast Cancer: Practice Strategies to Promote Medication Adherence

By Robert J. Ferguson, PhD; Madelaine C. Kuiper, NP; Maryam Lustberg, MD, MPH

Breast Cancer

Video Library

The Academy of Oncology Nurse & Patient Navigators (AONN+) and Eli Lilly and Company Medical Affairs are pleased to present a live webinar designed to facilitate conversations with patients regarding adherence to breast cancer treatments. Attendees will have an opportunity to participate in a live Q&A following the presentation.

LBA Category II: Care Coordination/Care Transitions

Coordination of Care/Care Transitions

October 2022 Vol 13, No 10

While it is generally recognized that oncology navigation programs can vary in structure, makeup, and domain of care, a common task expected of all navigators is identifying potential or existing barriers to cancer care.

LBA Category III: Patient Advocacy/Patient Empowerment

Patient Advocacy/Empowerment

October 2022 Vol 13, No 10

All Articles

Page 53 of 283

Connect with Us

Subscribe Today!

I'd like to receive:

Please enter your mailing address.